SCHEMBL7170227

SCHEMBL7170227

O=C1c2ccccc2C(=O)N1CC1=COc2ccc(F)cc2N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.46
CASP3 P42574 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.40
PKM P14618 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.40
NR3C2 P08235 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
RPS6KA2 Q15349 1/20 0.38
GRM5 P41594 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18669095 0.67 RPS6KA2 (0.53) CASP3RPS6KA2GRM5NPC1RAB9A
SCHEMBL18669187 0.66 ACHE (0.61) CASP3SMN1; SMN2ADRA1DADRA1AADRA1B
SCHEMBL26625800 0.66 ACHE (0.61) CASP3SMN1; SMN2ADRA1DADRA1AADRA1B
SCHEMBL18668918 0.66 CASP3 (0.54) CASP3SMN1; SMN2ADRA1DADRA1AADRA1B
SCHEMBL2644044 0.65 CASP3 (0.87) CASP3ADRA1DADRA1AADRA1BALDH1A1
SCHEMBL11618643 0.65 UBE2N (0.67) EGFRCASP3SMN1; SMN2PKMTSHR
SCHEMBL2478397 0.64 P2RX7 (0.52) CASP3TSHRKMT2ARPS6KA2GRM5
SCHEMBL2578279 0.64 CASP3 (0.51) EGFRCASP3SMN1; SMN2ADRA1DADRA1A
SCHEMBL3835155 0.64 MAPT (0.48) KMT2AALDH1A1POLBLMNAMAPT
SCHEMBL7170230 0.64 SMN1; SMN2 (0.45) CASP3SMN1; SMN2PKMTSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6573377-B1 Antitumor agent capable of showing its efficacy even against 5- FU drug resistant tumors DAIICHI PHARMACEUTICALS CO., LTD. (JP) 2003-06-03 US disclosed
US-6552018-B1 As antitumor agents DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-1103551-A1 PYRAZOLE DERIVATIVES AND SALTS THEREOF DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-05-30 EP disclosed
US-6169086-B1 AN ANTITUMOR AGENT FOR TREATING TUMOR RESISTANT TO 5-FLUOROURACIL TYPE DRUGS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed